Drawing for ZARVUMYS

USPTO serial 97700115

ZARVUMYS

Reviewed by CopyMark Law Group

Status 734Notice of Allowance
Filing date
Status date
Registration date
—
Examiner
PODESTA, GIDETTE
Law office
INTENT TO USE SECTION

What this means

The USPTO has issued a Notice of Allowance. To complete registration you generally need to file a Statement of Use or an extension request before the deadline.

Status 734: Status 734 means the fifth and typically final extension to file a Statement of Use was granted. You must file an acceptable Statement of Use before this last extension expires or the application will abandon.

Need help with ZARVUMYS?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Get help with this Notice of Allowance, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $324*

Plus Government fees of $125

Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Tiffany Trunko

Tiffany Trunko ELI LILLY AND COMPANYLILLY CORPORATE CENTERINDIANAPOLIS, IN 46285United States

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, blood diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal diseases and disorders, headaches, hearing loss, heart failure, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, mental disorders, metabolic diseases and disorders, migraines, multiple sclerosis, neurodegenerative diseases and disorders, neurological disorders, obesity, osteoarthritis, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, vascular diseasesACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Aug 8, 2026EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Aug 8, 2026EX5GSOU EXTENSION 5 GRANTED—
Aug 8, 2026AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
May 12, 2026TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
May 12, 2026ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
May 12, 2026REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Apr 28, 2026EXT5SOU EXTENSION 5 FILED—
Apr 28, 2026EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Oct 6, 2025EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Oct 6, 2025EX4GSOU EXTENSION 4 GRANTED—
Oct 6, 2025EXT4SOU EXTENSION 4 FILED—
Oct 6, 2025EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Apr 21, 2025EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Apr 21, 2025EX3GSOU EXTENSION 3 GRANTED—
Apr 21, 2025EXT3SOU EXTENSION 3 FILED—
Apr 21, 2025EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jul 24, 2024EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Jul 24, 2024EX2GSOU EXTENSION 2 GRANTED—
Jul 24, 2024EXT2SOU EXTENSION 2 FILED—
Jul 24, 2024EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Mar 29, 2024EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Mar 28, 2024EX1GSOU EXTENSION 1 GRANTED—
Mar 28, 2024EXT1SOU EXTENSION 1 FILED—
Mar 28, 2024EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Nov 14, 2023NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Sep 19, 2023NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Sep 19, 2023PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Aug 30, 2023NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Aug 14, 2023CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Aug 14, 2023DOCKASSIGNED TO EXAMINER—
Dec 5, 2022NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Dec 5, 2022NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance